Abstract 851P
Background
Acute myeloid leukemia (AML) is a clonal malignancy of the stem cell precursors of the myeloid lineage associate with uncontrolled proliferation and impaired differentiation of hematopoietic stem cells. Among the different genes found amplified in AML, the oncogene MYC is one of the prognostic factors with an impact of AML. Albeit MYC is a well know factor associated with the uncontrolled proliferation of AML, the mechanism that led to the oncogenesis established by MYC are not well known. Zebrafish has recently emerged as a valid model organism to study cancer development because of its genetic accessibility.
Methods
After the generation of a transgenic zebrafish line expressing the human MYC under the control of the neutrophils-specific promoter lysozyme (lyz:hMYC), we proceeded with FACS analysis of adult whole kidney marrow (WKM) of lyz:hMYC fish. Immunohistochemical analysis (IHC) of whole zebrafish was made to check the infiltration of cells and possible metastasis. May-Grunwald stain was made to check the kidney marrow population. Gene expression profile of WKM was performed to check the expression of genes associated with myc and its patthway. We conducted a Metagenomic analysis on possible variations in the intestinal microbiota associated with the disease causing its progression.
Results
FACS analysis of lyz:hMYC zebrafish revealed the expansion of myeloid cells with a significant reduction of erythroid cells, associated with anemia. The IHC analysis of whole lyz:hMYC zebrafish showed infiltration of myeloid cells into different organs confirming that those cells can proliferate unconditionally and metastasise. May-Grunwald analysis showed a higher number of blast cells unable to differentiate towards mature granulocytes in lyz:hMYC zebrafish than in their wild type siblings. The gene expression profile of WKM demonstrated the overexpression of exogenous MYC and of endogenous myc, suggesting a positive auto-regulation of MYC. Metagenomic analysis revealed that the gut microbes of AML fish were significantly altered with the possibility to be associated the progression of AML.
Conclusions
The model developed here is an excellent tool to further understand the mechanisms involved in MYC-induced AML and the relevance of gut microbiota on this disease.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University of Murcia.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
832P - Characterisation of EXS73565: A potent and selective MALT1 inhibitor with low drug-drug interaction risk and potential in lymphoma
Presenter: Major Gooyit
Session: Poster session 18
833P - New targets for adult T cell leukemia/lymphoma (ATLL): A map for ATLL immunotherapy
Presenter: Zahra Rezaei Borojerdi
Session: Poster session 18
834P - Phase II clinical study of VR-CAP regimen for first-line treatment of marginal zone lymphoma
Presenter: Junfeng Chu
Session: Poster session 18
835P - A safe and effective immunochemotherapy with oral sobuzoxane and etoposide for untreated diffuse large B cell lymphoma patients aged 80 and over
Presenter: Kaname Miyashita
Session: Poster session 18
838P - Matching-adjusted indirect comparison (MAIC) of axicabtagene ciloleucel (axi-cel) and epcoritamab (epcor) in relapsed/refractory (R/R) large B cell lymphoma (LBCL) after at least two prior systemic therapies (3L+)
Presenter: Olalekan Oluwole
Session: Poster session 18
840P - Genomic landscape, immune characteristics and prognostic mutation signature of extranodal NK/T cell lymphoma, nasal type in China
Presenter: Yue Chai
Session: Poster session 18
841P - Ki67-revised risk index to risk-stratify patients with extra-nodal natural killer/T cell lymphoma
Presenter: Shuo Li
Session: Poster session 18